A detailed history of Weik Capital Management transactions in Biogen Inc. stock. As of the latest transaction made, Weik Capital Management holds 1,350 shares of BIIB stock, worth $234,616. This represents 0.13% of its overall portfolio holdings.

Number of Shares
1,350
Previous 1,440 6.25%
Holding current value
$234,616
Previous $310,000 0.65%
% of portfolio
0.13%
Previous 0.13%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$190.52 - $236.72 $17,146 - $21,304
-90 Reduced 6.25%
1,350 $312,000
Q1 2024

May 14, 2024

BUY
$212.02 - $267.71 $38,163 - $48,187
180 Added 14.29%
1,440 $310,000
Q4 2023

Feb 13, 2024

SELL
$222.59 - $267.94 $61,212 - $73,683
-275 Reduced 17.92%
1,260 $326,000
Q3 2023

Nov 13, 2023

BUY
$253.3 - $285.89 $388,815 - $438,841
1,535 New
1,535 $394,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Weik Capital Management Portfolio

Follow Weik Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Weik Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Weik Capital Management with notifications on news.